Profile data is unavailable for this security.
About the company
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
- Revenue in GBP (TTM)396.00k
- Net income in GBP-3.14m
- Incorporated2014
- Employees9.00
- LocationTheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 162 531 5090
- Websitehttps://evgen.com/
Mergers & acquisitions
Acquired company | TCF:LSE since announced | Transaction value |
---|---|---|
Chronos Therapeutics Ltd | -22.32% | 4.33m |